Harmony Biosciences' second quarter revenue grew 30% to $261.3M, beating estimates while the company reiterates FY26 guidance.

Harmony Biosciences reported record second quarter 2026 net revenue of $261.3 million, a 30% increase year-over-year, driven by continued strong demand for WAKIX. Diluted earnings per share came in at $1.28. The company reiterated its full-year 2026 WAKIX net revenue guidance of $1.0 billion to $1.04 billion.

Key Highlights

• WAKIX net revenue grew 30% year-over-year to a record $261.3 million, confirming the company's pre-announced figure of approximately $261 million.
• The average number of patients on WAKIX increased by 450 in the quarter to approximately 8,950.
• The company shared positive initial Phase 1 data for its orexin-2 agonist BP-205 and confirmed the FDA accepted its New Drug Application for Pitolisant GR with a target PDUFA date of April 1, 2027.